Soligenix announced that the FDA has provided the company with a Refusal to File letter for its HyBryte – synthetic hypericin – new drug application – NDA – in the treatment of early stage cutaneous T-cell lymphoma, a rare cancer and area of unmet medical need affecting over 25,000 patients in the U.S. Upon preliminary review, the FDA determined that the NDA, submitted on December 14, 2022, was not sufficiently complete to permit substantive review. Soligenix first learned of the RTF decision via this letter and is reviewing its contents to determine the appropriate next steps, which includes, but is not limited to, requesting a Type A meeting with the FDA to clarify and respond to the issues identified in the letter and to seek additional guidance concerning information that the agency would require for a resubmitted NDA to be deemed acceptable to file.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SNGX:
- Soligenix Plunges as FDA Refuses to Review Drug Application
- Soligenix implementing 1-for-15 reverse stock split
- Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
- Soligenix’s RiVax vaccine shows non-human primate protection vs. ricin toxin
- Soligenix initiates Phase 2 clinical trial of SGX302
